Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
J Neurol ; 268(4): 1544-1554, 2021 Apr.
Article in English | MEDLINE | ID: mdl-33140239

ABSTRACT

Chimeric antigen receptor (CAR)-expressing T cells now offer an effective treatment option for people with previously refractory B cell malignancies and are under development for a wide range of other tumours. However, neurological toxicity is a common complication of CAR-T cell therapy, seen in over 50% of recipients in some cohorts. Since 2018, the term immune effector cell-associated neurotoxicity syndrome (ICANS) has been used to describe and grade neurotoxicity seen after CAR-T cells and other similar therapies. ICANS following CAR-T therapy is usually self-limiting but can necessitate admission to the intensive care unit and is rarely fatal. As CAR-T therapies enter routine clinical practice, it is important for neurologists to be aware of the nature of neurological complications. Here, we summarise the clinical manifestations, mechanisms, investigations and recommended treatment of CAR-T-related neurotoxicity, focusing on the licensed CD19 products.


Subject(s)
Nervous System Diseases , Neurotoxicity Syndromes , Receptors, Chimeric Antigen , Antigens, CD19 , Humans , Immunotherapy, Adoptive , Nervous System Diseases/etiology , Nervous System Diseases/therapy , Neurotoxicity Syndromes/etiology , Neurotoxicity Syndromes/therapy
2.
Br J Haematol ; 156(5): 573-87, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22233151

ABSTRACT

Observations in human tumours, as well as mouse models, have indicated that telomere dysfunction may be a key event driving genomic instability and disease progression in many solid tumour types. In this scenario, telomere shortening ultimately results in telomere dysfunction, fusion and genomic instability, creating the large-scale rearrangements that are characteristic of these tumours. It is now becoming apparent that this paradigm may also apply to haematological malignancies; indeed these conditions have provided some of the most convincing evidence of telomere dysfunction in any malignancy. Telomere length has been shown in several malignancies to provide clinically useful prognostic information, implicating telomere dysfunction in disease progression. In these malignancies extreme telomere shortening, telomere dysfunction and fusion have all been documented and correlate with the emergence of increased genomic complexity. Telomeres may therefore represent both a clinically useful prognostic tool and a potential target for therapeutic intervention.


Subject(s)
Hematologic Neoplasms/genetics , Telomere/physiology , Acute Disease , Bone Marrow Diseases/genetics , Disease Progression , Genomic Instability , Humans , Leukemia/genetics , Lymphoma, B-Cell/genetics , Multiple Myeloma/genetics , Prognosis , Telomere Shortening/genetics
SELECTION OF CITATIONS
SEARCH DETAIL
...